Long Non-Coding RNA LINC01123 Facilitates Cholangiocarcinoma Aggravation by Targeting miR-641

Area of Science:

• Molecular oncology
• Cancer biology

Background:

• Cholangiocarcinoma (CCA) is a challenging malignancy with limited treatment options.
• Long non-coding RNAs (LncRNAs) like LINC01123 play a role in cancer progression by regulating gene expression.
• Understanding the role of LINC01123 in CCA is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To investigate the association between LINC01123 and CCA.
• To elucidate the underlying molecular mechanism of LINC01123 in CCA progression.
• To identify LINC01123 as a potential therapeutic target for CCA management.

Main Methods:

• Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to measure LINC01123 and miR-641 expression in 128 CCA patient samples.
• Cell counting Kit-8 (CCK-8), transwell migration, and invasion assays to assess the biological functions of LINC01123 and miR-641 in CCA cells.
• Dual luciferase reporter assays and rescue experiments to investigate the regulatory mechanism.

Main Results:

• LINC01123 expression was significantly higher in CCA tissues and cells compared to normal controls.
• LINC01123 promoted CCA cell proliferation, migration, and invasion.
• LINC01123 expression was negatively correlated with miR-641 expression, indicating LINC01123 downregulates miR-641 to drive CCA progression.
• Elevated LINC01123 levels correlated with lymph node metastasis and advanced TNM stage.

Conclusions:

• LINC01123 is upregulated in CCA and promotes tumor progression by targeting miR-641.
• LINC01123 serves as a potential diagnostic biomarker and therapeutic target for cholangiocarcinoma.